In this exciting webinar co-hosted by GEN and Clinical OMICs, we explored the intratumoral administration of autologous, non-manipulated myeloid dendritic cells in combination with immune checkpoint inhibitors in patients with advanced solid tumors and in combination with the oncolytic virus talimogene laherparepvec (Imlygic®) in patients with advanced melanoma in phase I clinical trials.
Additionally, we heard how on-treatment biopsies are analyzed for cellular changes with immunohistochemistry and multiplexed immunofluorescence, which could serve as a surrogate biomarker.
